var title_f1_54_1888="Pathologic skin picking arm";
var content_f1_54_1888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Psychogenic excoriation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sharply demarcated erosions, ulcerations, and purpuric patches in a 15-year-old girl with anxiety disorder. Lesions were restricted to areas she could reach and healed completely after a week of occlusive dressing. All lesions cleared following mental health counseling.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Bernard Cohen, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1888=[""].join("\n");
var outline_f1_54_1888=null;
var title_f1_54_1889="Bard sewing technique";
var content_f1_54_1889=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F55669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F55669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Bard EndoCinch endoscopic sewing technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 134px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard I Rothstein, MD and Charles Filipi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1889=[""].join("\n");
var outline_f1_54_1889=null;
var title_f1_54_1890="PVOD CT image";
var content_f1_54_1890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71206&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Computed tomographic (CT) image of pulmonary veno-occlusive disease (PVOD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lung base shows numerous thickened septal lines (thin blue arrow) and patchy foci of ground glass attenuation (thin red arrow). The arteries are enlarged relative to bronchi (thick red arrow), whereas pulmonary veins appear of normal caliber (thick blue arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mandel J, Mark E, Hales C. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000; 162:1964. Official Journal of the American Thoracic Society &copy; American Lung Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1890=[""].join("\n");
var outline_f1_54_1890=null;
var title_f1_54_1891="Acute otitis media";
var content_f1_54_1891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63268&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Acute otitis media",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Examples of the white, bulging tympanic membrane seen in acute otitis media. The \"B\" panel also demonstrates marked erythema along the handle of the malleus and an air-fluid level in the anterosuperior portion of the tympanic membrane.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Alejandro Hoberman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1891=[""].join("\n");
var outline_f1_54_1891=null;
var title_f1_54_1892="Left ventricular hypertrophy parasternal long axis echo";
var content_f1_54_1892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/73329/palaxlvh_conv.mp4?title=Left+ventricular+hypertrophy+parasternal+long+axis+echo\" style=\"width:320px;height:256px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left ventricular hypertrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The parasternal long axis view from a 2-D echocardiogram shows marked thickening of the interventricular septum and posterior left ventricular (LV) wall as a result of hypertrophy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1892=[""].join("\n");
var outline_f1_54_1892=null;
var title_f1_54_1893="Dextromethorphan and chlorpheniramine: Patient drug information";
var content_f1_54_1893=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dextromethorphan and chlorpheniramine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/30/11749?source=see_link\">",
"     see \"Dextromethorphan and chlorpheniramine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6803352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coricidin&reg; HBP Cough &amp; Cold [OTC];",
"     </li>",
"     <li>",
"      Dimetapp&reg; Children&rsquo;s Long Acting Cough Plus Cold [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Children&rsquo;s Cough &amp; Cold Long-Acting [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; DM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Softchews&reg; Cough &amp; Runny Nose [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop coughing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dextromethorphan, chlorpheniramine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697679",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is not for coughs due to smoking or lung disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12164 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-4B2100FB5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1893=[""].join("\n");
var outline_f1_54_1893=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6803352\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018945\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018947\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018946\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018951\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018952\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018954\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018949\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018950\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018955\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018956\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/30/11749?source=related_link\">",
"      Dextromethorphan and chlorpheniramine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_54_1894="Supraglottic anatomy";
var content_f1_54_1894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 557px\">",
"   <div class=\"ttl\">",
"    Anatomy of the supraglottic larynx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 537px; height: 488px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1894=[""].join("\n");
var outline_f1_54_1894=null;
var title_f1_54_1895="Aluminum hydroxide and magnesium hydroxide: Drug information";
var content_f1_54_1895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide and magnesium hydroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/2/24612?source=see_link\">",
"    see \"Aluminum hydroxide and magnesium hydroxide: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/3/19511?source=see_link\">",
"    see \"Aluminum hydroxide and magnesium hydroxide: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alamag [OTC];",
"     </li>",
"     <li>",
"      Mag-Al Ultimate [OTC];",
"     </li>",
"     <li>",
"      Mag-Al [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diovol&reg;;",
"     </li>",
"     <li>",
"      Diovol&reg; Ex;",
"     </li>",
"     <li>",
"      Gelusil&reg; Extra Strength;",
"     </li>",
"     <li>",
"      Mylanta&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F132530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antacid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F132522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyperacidity:",
"     </b>",
"     Oral: OTC labeling:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Liquid",
"     </i>",
"     (aluminum hydroxide 200 mg and magnesium hydroxide 200 mg per 5 mL): 10-20 mL 4 times/day (maximum:80 mL/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Suspension",
"     </i>",
"     (aluminum hydroxide 500 mg and magnesium hydroxide 500 mg per 5 mL): 10-20 mL 4 times/day, between meals and at bedtime (maximum: 45 mL/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Tablet",
"     </i>",
"     (aluminum hydroxide 300 mg and magnesium hydroxide 150 mg): 1-2 tablets after meals or at bedtime, or as needed (maximum: 16 tablets/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F10432252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/3/19511?source=see_link\">",
"      see \"Aluminum hydroxide and magnesium hydroxide: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hyperacidity:",
"     </b>",
"     Oral: OTC labeling: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F132523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F132524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aluminum and/or magnesium may accumulate in severe renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F132513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Mag-Al:  Aluminum hydroxide 200 mg and magnesium hydroxide 200 mg per 5 mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol, sodium 4 mg/5 mL; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mag-Al Ultimate: Aluminum hydroxide 500 mg and magnesium hydroxide 500 mg per 5 mL (20 mL) [contains propylene glycol, sodium 4 mg/5 mL; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alamag: Aluminum hydroxide 300 mg and magnesium hydroxide 150 mg [contains phenylalanine 2.63 mg; wild cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F132502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9405836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid, suspension: Shake well before use; administer 1-3 hours after meals when stomach acidity is highest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Chew tablet thoroughly before swallowing or allow tablets to dissolve slowly in mouth. Follow with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F132514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antacid for symptoms related to hyperacidity associated with heartburn, hiatal hernia, upset stomach, peptic ulcer, peptic esophagitis, or gastritis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F132528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, chalky taste,  cramping, fecal discoloration (white speckles), fecal impaction, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia (rare), hypermagnesemia (rare)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10432064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypophosphatemia: Prolonged antacid therapy may result in hypophosphatemia; aluminum in antacid may form insoluble complexes with phosphate leading to decreased phosphate absorption in the GI tract. Rarely, severe hypophosphatemia can lead to anorexia, muscle weakness, malaise, and osteomalacia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; avoid use in severe renal impairment; hypermagnesemia or aluminum intoxication may occur in severe renal impairment, particularly with prolonged use. Aluminum intoxication may lead to osteomalacia or dialysis encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use with caution; the elderly may be predisposed to diarrhea or constipation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Patients with renal disease or on a magnesium-restricted diet should consult a healthcare provider prior to use. Unless directed by a physician, do not use for &gt;2 weeks or exceed the recommended daily dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F132508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfacalcidol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Magnesium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: May increase the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: May enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of calcium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of calcium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Aluminum Hydroxide may decrease the serum concentration of Chenodiol.  Management: Consider administration of chenodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citric Acid Derivatives: May increase the absorption of Aluminum Hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Aluminum Hydroxide may diminish the therapeutic effect of Deferasirox.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Magnesium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Aluminum Hydroxide may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Magnesium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., magnesium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethambutol: Aluminum Hydroxide may decrease the absorption of Ethambutol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Antacids may decrease the serum concentration of Fexofenadine.  Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Aluminum Hydroxide may decrease the serum concentration of Levothyroxine.  Management: Separate administration of oral levothyroxine and aluminum hydroxide by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Misoprostol: Antacids may enhance the adverse/toxic effect of Misoprostol. More specifically, concomitant use with magnesium-containing antacids may increase the risk of diarrhea.  Management: Avoid concomitant use of misoprostol and magnesium-containing antacids. In patients requiring antacid therapy, employ magnesium-free preparations. Monitor for increased adverse effects (e.g., diarrhea, dehydration).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Aluminum Hydroxide. Management: In patients with severe renal dysfunction, consider avoiding this combination of agents.  Administering agents at least 2 hours apart may help minimize the interaction(s).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Magnesium Salts may decrease the serum concentration of Mycophenolate.  Management: Separate doses of mycophenolate and oral magnesium salts. Monitor for reduced effects of mycophenolate if taken concomitant with oral magnesium salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Magnesium Salts may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Magnesium Salts may decrease the serum concentration of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral magnesium salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: Antacids may decrease the serum concentration of QuiNINE.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Magnesium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Laxatives may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of sodium polystyrene sulfonate with magnesium-containing laxatives may result in metabolic alkalosis or with sorbitol may result in intestinal necrosis.  Management: Avoid concomitant use of sodium polystyrene sulfonate (rectal or oral) and magnesium-containing laxatives or sorbitol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Aluminum Hydroxide. More specifically, concomitant use of these agents  may increase the risk for intestinal obstruction. Management: Monitor for signs/symptoms of intestinal obstruction with concomitant use of calcium polystyrene sulfonate and aluminum hydroxide. Adequate fluid intake, laxative use, alternative antacid agents, and/or limiting duration of therapy may help reduce risks.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Aluminum Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and aluminum hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Magnesium Hydroxide may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and magnesium hydroxide by at least 2 hours whenever possible in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Magnesium Salts may decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Magnesium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Magnesium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Aluminum Hydroxide may decrease the serum concentration of Ursodiol.  Management: Consider administration of ursodiol 2 hours before or 6 hours after aluminum-containing antacid products to prevent adsorption in the gastrointestinal tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Aluminum Hydroxide. Specifically, the absorption of aluminum may be increased, leading to increased serum aluminum concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14286993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14286994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F132516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken 1-3 hours after meals. Some products may contain sodium and/or phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Concentrate",
"     </b>",
"     (Maalox TC Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600-300 mg/5 mL (30 mL): $0.53",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F132517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Fanta (TW);",
"     </li>",
"     <li>",
"      Lederscan (HK);",
"     </li>",
"     <li>",
"      Maalox (AT, BB, BS, CZ, DE, FR, GB, GR, HN, IE, IL, IT, JM, NL, PE, PH, PY, TH, TT, UY);",
"     </li>",
"     <li>",
"      Maalox Plus (PE)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8614 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1895=[""].join("\n");
var outline_f1_54_1895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132519\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132520\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132530\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132522\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10432252\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132523\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132524\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132513\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132502\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9405836\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132514\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132528\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10432064\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298723\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132508\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286993\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14286994\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132516\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322976\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132517\">",
"      International Brand Names",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8614\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8614|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/2/24612?source=related_link\">",
"      Aluminum hydroxide and magnesium hydroxide: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/3/19511?source=related_link\">",
"      Aluminum hydroxide and magnesium hydroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_54_1896="Prednisolone (systemic): Pediatric drug information";
var content_f1_54_1896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednisolone (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40376?source=see_link\">",
"    see \"Prednisolone (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/12/29894?source=see_link\">",
"    see \"Prednisolone (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flo-Pred&trade;;",
"     </li>",
"     <li>",
"      Millipred&trade;;",
"     </li>",
"     <li>",
"      Millipred&trade; DP;",
"     </li>",
"     <li>",
"      Orapred ODT&reg;;",
"     </li>",
"     <li>",
"      Orapred&reg;;",
"     </li>",
"     <li>",
"      Pediapred&reg;;",
"     </li>",
"     <li>",
"      Veripred&trade; 20",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hydeltra T.B.A.&reg;;",
"     </li>",
"     <li>",
"      Novo-Prednisolone;",
"     </li>",
"     <li>",
"      Pediapred&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10507771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Systemic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bronchopulmonary dysplasia, treatment:",
"     <b>",
"      See Dosing: Usual",
"     </b>",
"     for dosing in infants",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10507851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40376?source=see_link\">",
"      see \"Prednisolone (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose depends upon condition being treated and response of patient; dosage for infants and children should be based on disease severity and patient response, rather than by rigid adherence to dosage guidelines by age, weight, or body surface area. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants: Bronchopulmonary dysplasia, treatment: 2 mg/kg/day divided twice daily for 5 days, followed by 1 mg/kg/day once daily for 3 days, followed by 1 mg/kg/dose every other day for 3 doses was used in 131 former premature neonates (postmenstrual age: &ge;36 weeks) with BPD; results showed  weaning of supplemental oxygen  was facilitated in patients with capillary  pCO",
"     <sub>",
"      2",
"     </sub>",
"     &lt;48.5 mm Hg and pulmonary acuity score &lt;0.5 (Bhandari, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     NIH Asthma Guidelines (NAEPP, 2007): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &lt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Asthma exacerbations (emergency care or hospital doses): 1-2 mg/kg/day in 2 divided doses (maximum: 60 mg/day) until peak expiratory flow is 70% of predicted or personal best",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Short-course \"burst\" (acute asthma): 1-2 mg/kg/day in divided doses 1-2 times/day for 3-10 days; maximum dose: 60 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Burst should be continued until symptoms resolve or patient achieves peak expiratory flow 80% of personal best; usually requires 3-10 days of treatment (~5 days on average); longer treatment may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Long-term treatment: 0.25-2 mg/kg/day given as a single dose in the morning or every other day as needed for asthma control; maximum dose: 60 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Asthma exacerbations (emergency care or hospital doses): 40-80 mg/day in divided doses 1-2 times/day until peak expiratory flow is 70% of predicted or personal best",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Short-course \"burst\" (acute asthma): 40-60 mg/day in divided doses 1-2 times/day for 3-10 days;",
"     <b>",
"      Note:",
"     </b>",
"     Burst should be continued until symptoms resolve and peak expiratory flow is at least 80% of personal best; usually requires 3-10 days of treatment (~5 days on average); longer treatment may be required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Long-term treatment: 7.5-60 mg daily given as a single dose in the morning or every other day as needed for asthma control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Children: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-inflammatory or immunosuppressive dose: 0.1-2 mg/kg/day in divided doses 1-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nephrotic syndrome:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Pediatric Nephrology Panel recommendations (Hogg, 2000):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Initial: 2 mg/kg/day or 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day given every day in 1-3 divided doses (maximum dose: 80 mg/day) until urine is protein-free or for 4-6 weeks, followed by maintenance dose: 2 mg/kg/dose or 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given every other day in the morning; gradually taper and discontinue after 4-6 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     6-week daily therapy, followed by 6-week alternate day therapy, may induce a higher rate of long remission compared to the standard of 4 weeks of daily therapy, followed by 4 weeks of alternate day therapy; however, a higher incidence of adverse effects may be seen with the longer regimen and the clinical benefit may be variable.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Relapse: Use high-dose daily steroid regimen (listed above) until urine is protein-free for 3 days; follow with maintenance-tapering course of alternate day therapy (maintenance dose listed above) for 4-6 weeks; subsequent therapy is determined by individual's response and number of relapses (Hogg, 2000)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     British Pediatric Nephrology Consensus Statement (Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, 1994):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First 3 episodes: Initial: 2 mg/kg/day or 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day given every day (maximum dose: 80 mg/day) until urine is protein-free for 3 consecutive days (maximum dose: 28 days), followed by 1-1.5 mg/kg/dose or 40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose (maximum: 60 mg/dose) given every other day for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Frequent relapses (long-term maintenance dose): 0.5-1 mg/kg/dose given every other day for 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: Oral: 5-60 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9506803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as base: 15 mg/5 mL (240 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sodium phosphate [strength expressed as base]: 5 mg/5 mL (120 mL); 15 mg/5 mL (237 mL, 473 mL); 25 mg/5 mL (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade;: 10 mg/5 mL (237 mL) [dye free, ethanol free; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orapred&reg;: 15 mg/5 mL (20 mL, 237 mL) [dye free; contains ethanol 2%, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediapred&reg;: 5 mg/5 mL (120 mL) [dye free; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Veripred&trade; 20: 20 mg/5 mL (237 mL) [dye free, ethanol free; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as acetate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flo-Pred&trade;: 15 mg/5 mL (52 mL) [contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade;: 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as base [dose-pack]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade; DP: 5 mg [scored; 12-day pack/48s]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade; DP: 5 mg [scored; 6-day pack/21s]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral, as sodium phosphate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orapred ODT&reg;: 10 mg, 15 mg, 30 mg [grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally disintegrating tablet, oral suspension, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10507846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer after meals or with food or milk to decrease GI upset.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flo-Pred&trade;: Administer using the provided calibrated syringe (supplied by manufacturer) to accurately measure the dose. Syringe should be washed prior to next use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orapred ODT&reg;: Do not cut, split, or break tablets; do not use partial tablets. Remove tablet from blister pack immediately prior to use. May swallow tablet whole or allow to dissolve on tongue.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10507783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dispense oral liquid formulations in tight, light-resistant containers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Storage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flo-Pred&trade;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not refrigerate; dispense in original container (to avoid loss of formulation during transfer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pediapred&reg; oral solution: Store at 4&deg;C to 24&deg;C (39&deg;F to 77&deg;F); may be refrigerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Orapred&reg; oral solution: Store in refrigerator at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Orapred ODT&reg;: Store at controlled room temperature at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) in blister pack; protect from moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10507772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of endocrine disorders, rheumatic disorders, collagen diseases, dermatologic diseases, allergic states, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, and GI diseases",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PrednisoLONE may be confused with predniSONE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pediapred&reg; may be confused with Pediazole&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prelone&reg; may be confused with PROzac&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9505594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy, CHF, edema, facial edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, insomnia, malaise, nervousness, pseudotumor cerebri, psychic disorders, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, facial erythema, hirsutism, petechiae, skin test reaction suppression, thin fragile skin, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Carbohydrate tolerance decreased, Cushing's syndrome, diabetes mellitus, growth suppression, hyperglycemia, hypernatremia, hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary adrenal axis suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, increased appetite, indigestion, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: LFTs increased (usually reversible)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, aseptic necrosis (humeral/femoral heads), fractures, muscle mass decreased, muscle weakness, osteoporosis, steroid myopathy, tendon rupture, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmus, eyelid edema, glaucoma, intraocular pressure increased, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased, impaired wound healing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10507773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prednisolone or any component; acute superficial herpes simplex keratitis; systemic fungal infections; varicella infections; live or live, attenuated virus vaccines (with immunosuppressive doses of corticosteroids)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10507775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; titrate to lowest effective dose. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Use with extreme caution in patients with respiratory tuberculosis or untreated systemic infections. Use with caution in patients with hypertension, heart failure, or renal impairment; long-term use has been associated with fluid retention and hypertension. Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to risk of GI bleeding and perforation. High-dose corticosteroids should not be used for management of head injury; increased mortality was observed in patients receiving high-dose I.V. methylprednisolone. Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred, especially during initial treatment with corticosteroids. Use with caution in patients with hepatic impairment, including cirrhosis; enhanced pharmacologic effect due to decreased metabolism and long-term use has been associated with fluid retention. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture; hypertrophic cardiomyopathy has been reported in premature neonates.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with diabetes; corticosteroids may alter glucose regulation, leading to hyperglycemia. Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use; consider routine eye exams in chronic users. Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis. Use with caution in patients with thyroid dysfunction; changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid patients. Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Use with caution in patients with thromboembolic tendencies or thrombophlebitis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with cataracts and/or glaucoma; with prolonged use, corticosteroids may result in ocular hypertension and/or glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation.  Corticosteroids should not be used in active ocular herpes simplex.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10507774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be tapered slowly and carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immunosuppression may occur; patients may be more susceptible to infections; prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral or fungal infections, activate latent opportunistic infections, or limit response to vaccines. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex; use caution in patients with a history of ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause osteoporosis (at any age) or inhibition of bone growth in pediatric patients. Use with caution in patients with osteoporosis. In a population-based study of children, risk of fracture was shown to be increased with &gt;4 courses of corticosteroids; underlying clinical condition may also impact bone health and osteoporotic effect of corticosteroids (Leonard, 2006).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use. Acute myopathy may occur with high doses, usually in patients with neuromuscular transmission disorders; myopathy may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed. Increased IOP may occur, especially with prolonged use; in children, increased IOP has been shown to be dose-dependent and produce a greater IOP in children &lt;6 years than older children (Lam, 2005). Rare cases of anaphylactoid reactions have been reported with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Orapred&reg; oral solution contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse; use prednisolone products containing sodium benzoate or benzoic acid with caution in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites. Flo-Pred&trade; oral suspension contains propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities, which can include metabolic acidosis, seizures, renal failure, and CNS depression; use prednisolone products containing propylene glycol with caution in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9505596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of PrednisoLONE (Systemic). PrednisoLONE (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). PrednisoLONE (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of PrednisoLONE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of PrednisoLONE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of PrednisoLONE (Systemic). Management: Consider prednisolone dose reductions in patients receiving ritonavir and monitor for increased adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10507782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic use of corticosteroids may require a diet with increased potassium, vitamins A, B",
"     <sub>",
"      6",
"     </sub>",
"     , C, D, folate, calcium, zinc, and phosphorus and decreased sodium",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D (Flo-Pred&trade;) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9505554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Prednisolone crosses the placenta; prior to reaching the fetus, prednisolone is converted by placental enzymes to prednisone. As a result, the amount of prednisolone reaching the fetus is ~8-10 times lower than the maternal serum concentration (healthy women at term; similar results observed with preterm pregnancies complicated by HELLP syndrome). Human studies have shown an association between first trimester corticosteroid use and oral clefts.  Additional adverse events in the fetus/neonate, including low birth weight, have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Women exposed to prednisolone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10507847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, weight, electrolytes, serum glucose; IOP (use &gt;6 weeks); bone mineral density (long-term use); children's height and growth",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10507844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10507845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well-absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 70% to 90% (concentration dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily in the liver, but also metabolized in most tissues, to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: In urine, principally as glucuronide and sulfate-conjugated metabolites",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10507849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/12/29894?source=see_link\">",
"      see \"Prednisolone (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; limit caffeine; do not decrease dose or discontinue without physician's approval; avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bhandari A, Schramm CM, Kimble C, et al, \"Effect of a Short Course of Prednisolone in Infants With Oxygen-Dependent Bronchopulmonary Dysplasia,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):e344-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1896/abstract-text/18245407/pubmed\" id=\"18245407\" target=\"_blank\">",
"        18245407",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hogg RJ, Portman RJ, Milliner D, et al, \"Evaluation and Management of Proteinuria and Nephrotic Syndrome in Children: Recommendations From a Pediatric Nephrology Panel Established at the National Kidney Foundation Conference on Proteinuria, Albuminuria, Risk, Assessment, Detection, and Elimination (PARADE),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2000, 105(6):1242-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1896/abstract-text/10835064/pubmed\" id=\"10835064\" target=\"_blank\">",
"        10835064",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"'Inactive' Ingredients in Pharmaceutical Products: Update (Subject Review). American Academy of Pediatrics Committee on Drugs,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1896/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lam DS, Fan DS, Ng JS, et al, \"Ocular Hypertensive and Anti-Inflammatory Responses to Different Dosages of Topical Dexamethasone in Children: A Randomized Trial,\"",
"      <i>",
"       Clin Experiment Ophthalmol",
"      </i>",
"      , 2005, 33(3):252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1896/abstract-text/15932528/pubmed\" id=\"15932528\" target=\"_blank\">",
"        15932528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leonard MB, \"Glucocorticoid-Induced Osteoporosis in Children: Impact of the Underlying Disease,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2007, 119 Suppl 2:S166-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1896/abstract-text/17332238/pubmed\" id=\"17332238\" target=\"_blank\">",
"        17332238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), \"Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,\"",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at:",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"      .",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, \"Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(2):151-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1896/abstract-text/8129444 /pubmed\" id=\"8129444 \" target=\"_blank\">",
"        8129444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16043 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1896=[""].join("\n");
var outline_f1_54_1896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505543\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507771\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444801\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507851\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9506803\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505545\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507846\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507783\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507772\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505495\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505594\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507773\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507775\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507774\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505596\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505597\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507782\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505553\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505554\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507847\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507844\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507845\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10507849\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16043\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16043|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/0/30723?source=related_link\">",
"      Prednisolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/13/43220?source=related_link\">",
"      Prednisolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/49/37650?source=related_link\">",
"      Prednisolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/27/40376?source=related_link\">",
"      Prednisolone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/12/29894?source=related_link\">",
"      Prednisolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_54_1897="Chloramphenicol: Drug information";
var content_f1_54_1897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chloramphenicol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/3/20532?source=see_link\">",
"    see \"Chloramphenicol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=see_link\">",
"    see \"Chloramphenicol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Chloromycetin&reg;;",
"     </li>",
"     <li>",
"      Chloromycetin&reg; Succinate;",
"     </li>",
"     <li>",
"      Diochloram&reg;;",
"     </li>",
"     <li>",
"      Pentamycetin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic infections: I.V.: 50-100 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4 g/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=see_link\">",
"      see \"Chloramphenicol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Other infections:",
"     </b>",
"     Children: Usual dosing range: I.V.: 50-100 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Meningitis:",
"     </b>",
"     I.V.: Infants &gt;30 days and Children: 75-100 mg/kg/day divided every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F149442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; monitor serum concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F149443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution; monitor serum concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g [contains sodium [~52 mg (2.25 mEq)/g]]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not administer I.M.; can be administered IVP over at least 1 minute at a concentration of 100 mg/mL, or I.V. intermittent infusion over 15-30 minutes at a final concentration for administration of &le;20 mg/mL.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F149489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, cyclophosphamide, cyclosporine, enalaprilat, esmolol, foscarnet, hydromorphone, labetalol, magnesium sulfate, meperidine, morphine, nicardipine, tacrolimus.",
"     <b>",
"      Incompatible",
"     </b>",
"     Fluconazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Ampicillin, cloxacillin, heparin, iohexol, iopamidol, iothalamate meglumine, ioxaglate meglumine and ioxaglate sodium, penicillin G sodium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Glycopyrrolate, metoclopramide.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of serious infections due to organisms resistant to other less toxic antibiotics or when its penetrability into the site of infection is clinically superior to other antibiotics to which the organism is sensitive; useful in infections caused by",
"     <i>",
"      Bacteroides",
"     </i>",
"     ,",
"     <i>",
"      H. influenzae",
"     </i>",
"     ,",
"     <i>",
"      Neisseria meningitidis",
"     </i>",
"     ,",
"     <i>",
"      Salmonella",
"     </i>",
"     , and",
"     <i>",
"      Rickettsia",
"     </i>",
"     ; active against many vancomycin-resistant enterococci",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F149491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Chloromycetin&reg; may be confused with chlorambucil, Chlor-Trimeton&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, delirium, depression, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, enterocolitis, glossitis, nausea, stomatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aplastic anemia, bone marrow suppression, granulocytopenia, hypoplastic anemia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic neuritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, hypersensitivity reactions, Gray syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to chloramphenicol or any component of the formulation; treatment of trivial or viral infections; bacterial prophylaxis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood dyscrasias:",
"     <b>",
"      [U.S. Boxed Warning]: Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) have occurred after both short-term and prolonged therapy. Monitor CBC frequently in all patients;",
"     </b>",
"     discontinue if evidence of myelosuppression. Irreversible bone marrow suppression may occur weeks or months after therapy. Avoid repeated courses of treatment. Should not be used for minor infections or when less potentially toxic agents are effective.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gray syndrome: Characterized by circulatory collapse, cyanosis, acidosis, abdominal distention, myocardial depression, coma, and death. Reaction appears to be associated with serum levels &ge;50 mcg/mL. May result from drug accumulation in patients with impaired hepatic or renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; reduced dosage recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose 6-phosphate dehydrogenase deficiency: Use with caution in patients with glucose 6-phosphate dehydrogenase deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Use with caution in neonates; due to risk of gray syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F149480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (strong), CYP2C9 (weak), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Chloramphenicol may decrease the metabolism of Anticonvulsants (Hydantoin). Anticonvulsants (Hydantoin) may decrease the serum concentration of Chloramphenicol. Increased chloramphenicol concentrations have also been seen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Chloramphenicol. Chloramphenicol may decrease the metabolism of Barbiturates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Strong) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a strong CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: CYP2C19 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyanocobalamin: Chloramphenicol may diminish the therapeutic effect of Cyanocobalamin. The expected hematologic response for the treatment of anemia may be opposed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Chloramphenicol may increase the serum concentration of CycloSPORINE (Systemic).  Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Strong) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Chloramphenicol may decrease the metabolism of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Chloramphenicol may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of chloramphenicol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Chloramphenicol may enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: Chloramphenicol may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F149430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: May decrease intestinal absorption of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     may have increased dietary need for riboflavin, pyridoxine, and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chloramphenicol crosses the placenta producing cord concentrations approaching maternal serum concentrations. An increased risk of teratogenic effects has not been identified for chloramphenicol and there have been no reports of fetal harm related to use of chloramphenicol in pregnancy. \"Gray Syndrome\" has occurred in premature infants and newborns receiving chloramphenicol. In most cases, chloramphenicol was started during the first 48 hours of life, but it has also occurred in older patients after high doses. Symptoms began after 3-4 days of therapy, starting with abdominal distention and continuing to progressive pallid cyanosis, vasomotor collapse, irregular respiration, and death within a few hours of symptom onset. Stopping therapy can reverse the process and allow complete recovery. There is one case report of an infant with gray baby syndrome after",
"     <i>",
"      in utero",
"     </i>",
"     exposure to a single maternal dose during labor, followed by a 10-fold overdose of chloramphenicol in the first day of life. The extent of the contribution of the single dose given during labor is unknown. The manufacturer recommends caution if used in a pregnant patient near term or during labor.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use with caution (AAP rates &ldquo;of concern&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F149421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chloramphenicol is excreted in human milk in both the active form and as inactive metabolites. Chloramphenicol is well absorbed following oral administration; however, metabolism and excretion are highly variable in infants and children. The half-life is also significantly prolonged in low birth weight infants. There have been documented toxicities in neonates and preterm infants when chloramphenicol has been used at therapeutic doses. The manufacturer recommends caution if using chloramphenicol in a breast-feeding infant. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F149422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May have increased dietary need for riboflavin, pyridoxine, and vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     . Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Chloramphenicol Sod Succinate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $35.93",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F149408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (baseline and every 2 days during therapy), periodic liver and renal function tests, serum drug concentration",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F149411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Therapeutic levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Meningitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak: 15-25 mcg/mL; toxic concentration: &gt;40 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Trough: 5-15 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Other infections:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Peak: 10-20 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Trough: 5-10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Timing of serum samples: Draw levels 0.5-1.5 hours after completion of I.V. dose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alfa Cloromicol (EC);",
"     </li>",
"     <li>",
"      Armisetin (TR);",
"     </li>",
"     <li>",
"      Biocaf (IL);",
"     </li>",
"     <li>",
"      Biophenicol (AT);",
"     </li>",
"     <li>",
"      Cebenicol (FR);",
"     </li>",
"     <li>",
"      Chemicetina (IT);",
"     </li>",
"     <li>",
"      Chloramphen (FI);",
"     </li>",
"     <li>",
"      Chloramphenicol (BE, CZ, NO);",
"     </li>",
"     <li>",
"      Chloramphenicol Faure, Ophthadoses (CH);",
"     </li>",
"     <li>",
"      Chloramphenicol RIT (BE);",
"     </li>",
"     <li>",
"      Chloranic (GR);",
"     </li>",
"     <li>",
"      Chlornitromycin (BG);",
"     </li>",
"     <li>",
"      Chlorocide S (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Chloromycetin (AR, BF, BJ, CI, CR, DO, EC, ES, ET, GB, GH, GM, GN, HN, IE, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, NI, PA, PK, PT, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Chloromycetin Eye Preparations (NZ);",
"     </li>",
"     <li>",
"      Chloromycetin Injection (AU);",
"     </li>",
"     <li>",
"      Chloroptic (IE, PK);",
"     </li>",
"     <li>",
"      Chlorsig (NZ);",
"     </li>",
"     <li>",
"      Cloftal (VE);",
"     </li>",
"     <li>",
"      Cloramfeni Ofteno (GT, MX, SV);",
"     </li>",
"     <li>",
"      Cloramidina Ophth Oint (ID);",
"     </li>",
"     <li>",
"      Cloran (MX);",
"     </li>",
"     <li>",
"      Cloranfenicol (VE);",
"     </li>",
"     <li>",
"      Clordil (MX);",
"     </li>",
"     <li>",
"      Cloromisan (PE);",
"     </li>",
"     <li>",
"      Cloroptic (CO);",
"     </li>",
"     <li>",
"      Clovicol (PH);",
"     </li>",
"     <li>",
"      Cogetine (TH);",
"     </li>",
"     <li>",
"      Colircusi Cloramfenicol (ES);",
"     </li>",
"     <li>",
"      Colsancetine (ID);",
"     </li>",
"     <li>",
"      Detreomycyna (PL);",
"     </li>",
"     <li>",
"      Enclor (SG);",
"     </li>",
"     <li>",
"      Exacol (MX);",
"     </li>",
"     <li>",
"      Fenicol (ID);",
"     </li>",
"     <li>",
"      Gemitin oftalmico (CN);",
"     </li>",
"     <li>",
"      Globenicol (NL);",
"     </li>",
"     <li>",
"      Grafacetin (ID);",
"     </li>",
"     <li>",
"      Helocetin (KP);",
"     </li>",
"     <li>",
"      Ikamicetin (ID);",
"     </li>",
"     <li>",
"      Isopto Fenicol (BE, PY);",
"     </li>",
"     <li>",
"      Kalmicetine (IN);",
"     </li>",
"     <li>",
"      Kemicetin (AT);",
"     </li>",
"     <li>",
"      Kemicetine (AE, BH, CY, EG, GB, HK, ID, IQ, IR, JO, KW, LB, LY, MY, OM, PT, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Kloramfenicol (DK, SE);",
"     </li>",
"     <li>",
"      Klorfen (PH);",
"     </li>",
"     <li>",
"      Klornik (PH);",
"     </li>",
"     <li>",
"      Lennacol (ZA);",
"     </li>",
"     <li>",
"      New-Lylo (TW);",
"     </li>",
"     <li>",
"      Ofenicol (PY);",
"     </li>",
"     <li>",
"      Oftadil (MX);",
"     </li>",
"     <li>",
"      Oftan-Akvakol (EE);",
"     </li>",
"     <li>",
"      Oleomycetin (DE);",
"     </li>",
"     <li>",
"      Optichlor (SG);",
"     </li>",
"     <li>",
"      Pharmacetin Otic (TH);",
"     </li>",
"     <li>",
"      Phenicol (IL);",
"     </li>",
"     <li>",
"      Posifenicol C (DE);",
"     </li>",
"     <li>",
"      Quemicitina (BR, CO);",
"     </li>",
"     <li>",
"      Reclor (IN);",
"     </li>",
"     <li>",
"      Septicol (CH);",
"     </li>",
"     <li>",
"      Septicyn (PH);",
"     </li>",
"     <li>",
"      Solu-Paraxin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Suismycetin (BB, BM, BS, BZ, GY, JM, PR, SR, TT);",
"     </li>",
"     <li>",
"      Synthomycin (RU);",
"     </li>",
"     <li>",
"      Unifenicol (BR);",
"     </li>",
"     <li>",
"      Vanafen Otologic (TH);",
"     </li>",
"     <li>",
"      Vanafen S (TH);",
"     </li>",
"     <li>",
"      Vanmycetin (IN);",
"     </li>",
"     <li>",
"      Vioclor (UY);",
"     </li>",
"     <li>",
"      Westenicol (MX);",
"     </li>",
"     <li>",
"      Xepanicol (ID, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly binds to 50S ribosomal subunits of susceptible organisms preventing amino acids from being transferred to growing peptide chains thus inhibiting protein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: To most tissues and body fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.5-1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol succinate: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.2-3.1 L/kg; decreased with hepatic or renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Chloramphenicol: ~60%; decreased with hepatic or renal dysfunction and in newborn infants",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol: Hepatic to metabolites (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol succinate: Hydrolyzed in the liver, kidney and lungs to chloramphenicol (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol: Oral: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chloramphenicol succinate: I.V.: ~70%; highly variable, dependent upon rate and extent of metabolism to chloramphenicol",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal renal function:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chloramphenicol: Adults: ~4 hours; Children 4-6 hours; Infants: Significantly prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chloramphenicol succinate: Adults: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     End-stage renal disease: Chloramphenicol: 3-7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic disease: Prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~30% as unchanged chloramphenicol succinate in adults, 6% to 80% in children; 5% to 15% as chloramphenicol)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ambrose PJ, &ldquo;Clinical Pharmacokinetics Of Chloramphenicol And Chloramphenicol Succinate,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1984, 9(3):222-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/6375931/pubmed\" id=\"6375931\" target=\"_blank\">",
"        6375931",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cocke JG Jr, &ldquo;Chloramphenicol Optic Neuritis. Apparent Protective Effects of Very High Daily Doses of Pyridoxine and Cyanocobalamin,&rdquo;",
"      <i>",
"       Am J Dis Child",
"      </i>",
"      , 1967, 114(4):424-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/6047242/pubmed\" id=\"6047242\" target=\"_blank\">",
"        6047242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doona M and Walsh JB, &ldquo;Use of Chloramphenicol as Topical Eye Medication: Time to Cry Halt?&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1995, 310(6989):1217-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/7767184/pubmed\" id=\"7767184\" target=\"_blank\">",
"        7767184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freundlich M, Cynamon H, Tamer A, et al, &ldquo;Management of Chloramphenicol Intoxication in Infancy by Charcoal Hemoperfusion,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1983, 103(3):485-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/6886919/pubmed\" id=\"6886919\" target=\"_blank\">",
"        6886919",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hammett-Stabler CA and Johns T, &ldquo;Laboratory Guidelines for Monitoring of Antimicrobial Drugs. National Academy of Clinical Biochemistry,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1998, 44(5):1129-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/9590397/pubmed\" id=\"9590397\" target=\"_blank\">",
"        9590397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kunin CM, Glazko AJ, and Finland M, &ldquo;Persistence of Antibiotics in Blood of Patients With Acute Renal Failure. II. Chloramphenicol and Its Metabolic Products in the Blood of Patients With Severe Renal Failure Disease or Hepatic Cirrhosis,&rdquo;",
"      <i>",
"       J Clin Invest",
"      </i>",
"      , 1959, 38(9):1498-508.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/14412753/pubmed\" id=\"14412753\" target=\"_blank\">",
"        14412753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Messick CR and Pendland SL, &ldquo;",
"      <i>",
"       In Vitro",
"      </i>",
"      Activity of Chloramphenicol Alone and in Combination With Vancomycin, Ampicillin, or RP 59500 (Quinupristin/Dalfopristin) Against Vancomycin-Resistant Enterococci,&rdquo;",
"      <i>",
"       Diagn Microbiol Infect Dis",
"      </i>",
"      , 1997, 29(3):203-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Montoro A, Cao A, Ordoqui E, et al, &ldquo;Contact Sensitivity to Chloramphenicol,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1995, 95:291.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nahata MC and Powell DA, &ldquo;Bioavailability and Clearance of Chloramphenicol After Intravenous Chloramphenicol Succinate,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1981, 30(3):368-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/7273601/pubmed\" id=\"7273601\" target=\"_blank\">",
"        7273601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Powell DA and Nahata MC, &ldquo;Chloramphenicol: New Perspectives on an Old Drug,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1982, 16(4):295-300.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/7040026/pubmed\" id=\"7040026\" target=\"_blank\">",
"        7040026",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramilo O, Kinane BT, and McCracken GH Jr, &ldquo;Chloramphenicol Neurotoxicity,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1988, 7(5):358-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/3380586/pubmed\" id=\"3380586\" target=\"_blank\">",
"        3380586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1991, 66(12):1270-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/1749296/pubmed\" id=\"1749296\" target=\"_blank\">",
"        1749296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunkel AR, Wispelwey B, and Scheld M, &ldquo;Bacterial Meningitis: Recent Advances in Pathophysiology and Treatment,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1990, 112(8):610-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/2183667/pubmed\" id=\"2183667\" target=\"_blank\">",
"        2183667",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1988, 15(4):254-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/3359738/pubmed\" id=\"3359738\" target=\"_blank\">",
"        3359738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(12):1353-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/2254575/pubmed\" id=\"2254575\" target=\"_blank\">",
"        2254575",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yunis AA, &ldquo;Chloramphenicol: Relation of Structure to Activity and Toxicity,&rdquo;",
"      <i>",
"       Annu Rev Pharmacol Toxicol",
"      </i>",
"      , 1988, 28:83-100.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?1/54/1897/abstract-text/3289495/pubmed\" id=\"3289495\" target=\"_blank\">",
"        3289495",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9241 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1897=[""].join("\n");
var outline_f1_54_1897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708673\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149436\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149484\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149440\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149462\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149441\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149442\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149443\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149410\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149395\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149415\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149489\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149414\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149491\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149482\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149418\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149399\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149480\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149404\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149430\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149420\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149447\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149421\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149422\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323057\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149408\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149411\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869368\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149398\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149417\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/3/20532?source=related_link\">",
"      Chloramphenicol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/35/4664?source=related_link\">",
"      Chloramphenicol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_54_1898="Management of splenic injury in the adult trauma patient";
var content_f1_54_1898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of splenic injury in the adult trauma patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/54/1898/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/54/1898/contributors\">",
"     Adrian A Maung, MD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/54/1898/contributors\">",
"     Lewis J Kaplan, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/54/1898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/54/1898/contributors\">",
"     Heidi L Frankel, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?1/54/1898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?1/54/1898/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?1/54/1898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen is one of the most commonly injured intra-abdominal organs. The diagnosis and prompt management of potentially life-threatening hemorrhage is the primary goal. The preservation of functional splenic tissue is secondary and in selected patients may be accomplished using nonoperative management or operative salvage techniques. Any attempt to salvage the spleen is abandoned in the face of ongoing hemorrhage or other life-threatening injuries. Emergent and urgent splenectomy remains a life-saving measure for many patients.",
"   </p>",
"   <p>",
"    This topic will discuss the diagnosis and management of splenic injury. The management of spontaneous splenic rupture related to infectious or hematologic diseases as opposed to injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H12#H12\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenic rupture'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SPLENIC ANATOMY AND PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spleen is located posterolaterally in the left upper quadrant of the abdomen beneath the left hemidiaphragm and lateral to the greater curvature of the stomach. The gross anatomy of the spleen is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7049?source=see_link&amp;anchor=H3#H3\">",
"     \"Surgical management of splenic injury in the adult trauma patient\", section on 'Anatomy of the spleen'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spleen is a major lymphopoietic organ, comprising approximately 25 percent of the total lymphoid mass of the body. Normal splenic function is important for opsonization of encapsulated organisms. Splenic physiology is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H3#H3\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Normal splenic function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic injury most commonly occurs following blunt trauma due to motor vehicle collisions (driver, passenger, or pedestrian). However, blunt splenic injury can also result from falls, sport-related activities, or assault [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/1\">",
"     1",
"    </a>",
"    ]. Penetrating splenic trauma is less common than blunt injury and is typically due to assault, but inadvertent impalement may also occur. Assault with a knife compared with gunshot or shotgun wounds is less likely to result in penetrating injury due to the spleen's protected location.",
"   </p>",
"   <p>",
"    Iatrogenic traumatic injuries to the spleen can result from surgical or endoscopic manipulation of the colon, stomach, pancreas, kidney, or with exposure and reconstruction of the proximal abdominal aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Most commonly, the primary mechanism is capsular tear, laceration from retraction devices, or tension on the spleen during manipulation of the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/5\">",
"     5",
"    </a>",
"    ]. The risk is greatest for patients undergoing colon resection. A study from the National Inpatient Sample (NIS) database found, among nearly a million patients, a 1 percent incidence of splenic injury during colorectal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/6\">",
"     6",
"    </a>",
"    ]. Transverse colectomy was the colon procedure most commonly associated with splenic injury. Other factors related to iatrogenic splenic injury include prior surgery, obesity, malignancy, diverticulitis, and peripheral artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRAUMA EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform initial resuscitation, diagnostic evaluation and management of the trauma patient with blunt or penetrating trauma based upon protocols from the Advanced Trauma Life Support (ATLS&reg;) program, established by the American College of Surgeons Committee on Trauma. The initial resuscitation and evaluation of the patient with blunt or penetrating abdominal or thoracic trauma is discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"       \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link\">",
"       \"Initial evaluation and management of abdominal stab wounds in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The spleen and liver are the most commonly injured intra-abdominal organs following blunt trauma. In up to 60 percent of patients, the spleen is the only organ injured [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/7\">",
"     7",
"    </a>",
"    ]. Specific elements of the history, physical examination and diagnostic evaluation pertaining to splenic injury are presented below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of trauma to the left-upper quadrant, left rib cage, or left flank should increase the suspicion for splenic injury. However, a negative history does not reliably exclude splenic injury. A penetrating object can injure the spleen even if the entrance wound is not in proximity to the spleen.",
"   </p>",
"   <p>",
"    The patient may complain of left upper abdominal, left chest wall, or left shoulder pain (ie, Kehr's sign). Kehr's sign is pain referred to the left shoulder that worsens with inspiration and is due to irritation of the phrenic nerve from blood adjacent to the left hemidiaphragm.",
"   </p>",
"   <p>",
"    Abdominal tenderness and peritoneal signs are the most common findings indicative of intra-abdominal injury; however, these are not sensitive or specific for splenic injury. Physical findings associated with splenic injury include left-upper quadrant or generalized abdominal tenderness, abdominal wall contusion or hematoma (eg, seat belt sign), as well as left lower chest wall tenderness, contusion, or instability due to rib fractures. However, an unremarkable physical examination does not exclude splenic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of injury, many patients have altered mental status (eg, neurologic injury, intoxication) or are intubated and sedated and cannot relate their symptoms or medical history. Every attempt should be made to identify any preexisting medical conditions by contacting the patient's primary care physician or family members. The presence of significant medical comorbidities and medical conditions requiring antiplatelet or anticoagulant medications needs to be determined as these may impact management decisions. A social history should be obtained to determine the feasibility of nonoperative management of splenic injury, if warranted. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Contraindications to nonoperative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A history of herbal medicine use is also important as some (eg, ginkgo biloba, saw palmetto, fish oil) have anticoagulant activity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link&amp;anchor=H36#H36\">",
"     \"Overview of herbal medicine and dietary supplements\", section on 'Surgical patients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of herbal medicine and dietary supplements\", section on 'Herb-drug interactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=see_link&amp;anchor=H28#H28\">",
"     \"Fish oil and marine omega-3 fatty acids\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Associated injuries",
"    </span>",
"    &nbsp;&mdash;&nbsp;With blunt abdominal trauma, lower rib fractures, pelvic fracture, and spinal cord injury may also be present [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The injuries associated with penetrating trauma depend upon the implement or missile trajectory. Injuries to adjacent organs including the heart, esophagus, aorta, stomach, diaphragm, pancreas, bowel, or left kidney can occur in conjunction with splenic laceration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link\">",
"     \"Initial evaluation and management of abdominal stab wounds in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the abdominal trauma patient commonly utilizes focused assessment with sonography in trauma (FAST exam), and computerized tomography (CT scan). The FAST exam is more useful in hemodynamically unstable patients; however, a negative FAST examination is not adequate to exclude splenic injury, particularly intraparenchymal injury. Diagnostic peritoneal",
"    <span class=\"nowrap\">",
"     aspiration/lavage",
"    </span>",
"    <span class=\"nowrap\">",
"     (DPA/DPL)",
"    </span>",
"    is less common, having been largely replaced by the FAST examination in most major trauma centers. The value of these tests in the diagnostic evaluation of the trauma patient is discussed in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H11#H11\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Ultrasound'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link&amp;anchor=H11#H11\">",
"       \"Initial evaluation and management of abdominal gunshot wounds in adults\", section on 'Ultrasound'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link&amp;anchor=H11#H11\">",
"       \"Initial evaluation and management of abdominal stab wounds in adults\", section on 'Ultrasound'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\", section on 'Diagnostic peritoneal lavage'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link&amp;anchor=H12#H12\">",
"       \"Initial evaluation and management of abdominal stab wounds in adults\", section on 'Diagnostic peritoneal tap and lavage'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link&amp;anchor=H12#H12\">",
"       \"Initial evaluation and management of abdominal gunshot wounds in adults\", section on 'Diagnostic peritoneal lavage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Specific diagnostic findings of splenic injury are described in the sections below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2380934350\">",
"    <span class=\"h3\">",
"     FAST findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of splenic injury observed with FAST examination include a finding of hypoechoic (ie, black) rim of subcapsular fluid or intraperitoneal fluid usually found around the spleen or in Morrison&rsquo;s pouch (hepatorenal space).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2380934357\">",
"    <span class=\"h3\">",
"     CT findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-injured patients, CT scan is typically performed with both oral (PO) and intravenous (IV) contrast. However, most trauma centers no longer administer PO contrast because scans performed without oral contrast, particularly in children, have sufficient detail to establish and grade splenic injury. For obvious reasons, non-intravenous contrast CT scan cannot establish the presence of active bleeding (ie, contrast blush, active extravasation). However, the risk of IV contrast administration to diagnose bleeding needs to be weighed against the risk of complications related to IV contrast (eg, contrast-induced nephropathy), particularly in elderly patients. A screening non-contrast CT scan may provide some adequate information.",
"   </p>",
"   <p>",
"    The differentiation between ascites and blood is made using the Hounsfield unit scale, which is a transformation of the linear attenuation coefficient of a material relative to water (at standard temperature and pressure). The Hounsfield unit of water (eg, ascites) is zero, and that of IV contrast 130. The value for blood varies depending upon whether it is clotted, and if so, the age of the clot. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=see_link&amp;anchor=H2#H2\">",
"     \"Principles of computed tomography of the chest\", section on 'General description'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CT scan findings that indicate splenic injury include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemoperitoneum &ndash; Localized fluid collections around the spleen (especially those with an elevated Hounsfield unit measurement) are highly suggestive of hemoperitoneum. Briskly bleeding splenic lacerations may establish blood density fluid throughout the abdomen.",
"     </li>",
"     <li>",
"      Hypodensity &ndash; Hypodense regions represent areas of parenchymal disruption, intraparenchymal hematoma or subcapsular hematoma.",
"     </li>",
"     <li>",
"      Contrast blush or extravasation &ndash; Contrast blush describes hyperdense areas within the splenic parenchyma that represent traumatic disruption or pseudoaneurysm of the splenic vasculature. Active extravasation of contrast implies ongoing bleeding and the need for urgent intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management approach'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2380934399\">",
"    <span class=\"h3\">",
"     Other imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain films, organ-based ultrasound imaging, and magnetic resonance imaging (MRI) are of limited value in the acute diagnosis of splenic injury.",
"   </p>",
"   <p>",
"    Plain films are generally nonspecific but may demonstrate rib fracture, or medial displacement of the gastric air bubble (ie, Balance sign) raising suspicion for a splenic injury.",
"   </p>",
"   <p>",
"    MRI and organ-based ultrasound examination may be time-consuming to perform, and may put the patient in a location of the hospital remote from ready access and intervention. However, MRI may be applicable in a subset of hemodynamically stable patients who cannot undergo CT scan (eg, allergic to IV contrast) [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/12\">",
"     12",
"    </a>",
"    ]. Noncontrast CT remains preferable for the acute diagnosis of splenic injury due to speed and accessibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SPLENIC INJURY GRADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Association for the Surgery of Trauma (AAST) has published a spleen injury grading scale based upon the anatomic injury identified on CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/13\">",
"     13",
"    </a>",
"    ]. The grade of injury and the degree of hemoperitoneum on CT scan relate to the success of nonoperative management, but do not consistently predict the need for initial operative intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Management approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The AAST criteria for hematoma and laceration for each splenic injury grade are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I &mdash; Hematoma: subcapsular, &lt;10 percent of surface area. Laceration: capsular tear &lt;1 cm in depth into the parenchyma (",
"      <a class=\"graphic graphic_picture graphicRef71599 \" href=\"UTD.htm?30/12/30919\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Grade II &mdash; Hematoma: subcapsular, 10 to 50 percent of surface area. Laceration: capsular tear, 1 to 3 cm in depth, but not involving a trabecular vessel.",
"     </li>",
"     <li>",
"      Grade III &mdash; Hematoma: subcapsular, &gt;50 percent of surface area OR expanding, ruptured subcapsular or parenchymal hematoma OR intraparenchymal hematoma &gt;5 cm or expanding. Laceration: &gt;3 cm in depth or involving a trabecular vessel.",
"     </li>",
"     <li>",
"      Grade IV &mdash; Laceration involving segmental or hilar vessels with major devascularization (ie, &gt;25 percent of spleen) (",
"      <a class=\"graphic graphic_picture graphicRef65830 \" href=\"UTD.htm?25/34/26151\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Grade V &mdash; Hematoma: shattered spleen. Laceration: hilar vascular injury which devascularizes spleen.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The AAST CT grade is not always concordant with the grade of injury identified in the operating room due to technical issues and variability of CT scan interpretation [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. A modified CT grading system has been proposed that may better identify those patients who would benefit from initial angiographic embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic injury can be initially managed with observation, angiographic embolization, or surgery depending upon the hemodynamic status of the patient, grade of splenic injury, and presence of other injuries and medical comorbidities. The management approach used may vary from institution to institution depending upon the availability of resources.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamically unstable &mdash; Based upon ATLS principles, the hemodynamically unstable trauma patient with a positive FAST scan or",
"      <span class=\"nowrap\">",
"       DPA/DPL",
"      </span>",
"      requires emergent abdominal exploration to determine the source of intraperitoneal hemorrhage [",
"      <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Trauma evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemodynamically stable &mdash; Hemodynamically stable patients with low-grade (I to III) blunt or penetrating splenic injuries without any evidence for other intra-abdominal injuries, active contrast extravasation, or a blush on CT, may be initially observed safely. In general, patients who meet the criteria for observation but who require intervention to manage extra-abdominal injuries (eg, leg fracture stabilization) can also be safely observed. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Observation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CT scan findings of contrast extravasation or vascular blush have higher failure rates for observational management [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/11\">",
"     11",
"    </a>",
"    ]. These patients may benefit from initial splenic embolization followed by continued observation to verify the success of the intervention. Another indication for embolization is intraparenchymal pseudoaneurysm formation. Splenic embolization is controversial for higher grade (IV, V) injuries and in patients older than 55. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Splenic embolization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Surgery is indicated in patients who cannot be adequately observed (due to limited resources or other injuries), are unlikely to tolerate a significant episode of hypotension, and those who fail nonsurgical management (ie, observation, embolization). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Failure of nonoperative management'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Operative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Whether the management approach adopted for trauma patients can be extrapolated to guide the management of iatrogenic splenic trauma is unclear. Although splenic salvage is sometimes attempted for iatrogenic splenic trauma that occurs during surgery, more than 70 percent of patients ultimately undergo splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/22\">",
"     22",
"    </a>",
"    ]. It is unclear whether this is truly necessary or due to surgeons&rsquo; &ldquo;discomfort&rdquo; at watching a slowly oozing low-grade injury that would then necessitate a second surgery if nonoperative management fails.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NONOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenic trauma was nearly uniformly managed with surgery prior to the introduction of nonoperative management algorithms in the pediatric population. What seemed initially to be a radical approach was adopted over time by the adult trauma community. Nonoperative management, encompassing both observation and embolization techniques, is used to manage 50 to 70 percent of cases, typically for patients with lower grade injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/23-26\">",
"     23-26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Splenic injury grading'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The rationale for nonoperative management is based upon the assumption that salvaging functional splenic tissue avoids the surgical and anesthetic risks and complications associated with laparotomy and abrogates the risk of postsplenectomy sepsis.",
"   </p>",
"   <p>",
"    However, immune competence after injury that does not require removal of the spleen (eg, embolization, partial splenectomy) depends on the immunologic functionality of the residual splenic tissue and does not appear to be grade specific. The small risk of postsplenectomy sepsis appears higher at the extremes of age, but may be influenced by concomitant immune deficiency from solid organ transplantation, malignancy, and HIV disease. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Immunocompetence after splenic injury'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Contraindications to nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoperative management is not appropriate in patients with hemodynamic instability, generalized peritonitis, or for patients with other intra-abdominal injuries requiring surgical exploration. Portal hypertension is a relative contraindication due to the increased venous pressures that may prevent clot formation and control of hemorrhage even after successful splenic embolization. Other relative contraindications include higher-grade splenic injury (&gt;Grade III), active contrast extravasation, large volume hemoperitoneum (though difficult to accurately quantify), refusal of blood transfusion in the setting of pre-existing anemia, or altered neurologic status precluding adequate serial abdominal examination.",
"   </p>",
"   <p>",
"    There is a higher failure rate of nonoperative management with increasing grade of injury, though all grades of splenic trauma can bleed and often in an unpredictable fashion [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The optimal management of hemodynamically stable patients with higher-grade (IV, V) injuries remains controversial, though grade V injuries are generally unsuitable for embolization due to vascular disruption. Some also consider Grade IV injuries to be a relative contraindication to splenic embolization. In one small retrospective review, 60 percent of patients with higher grade injuries were taken directly to the operating room. The remaining patients were managed nonoperatively with 55 percent of these patients ultimately requiring surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/29\">",
"     29",
"    </a>",
"    ]. We prefer to initially manage hemodynamically stable patients with Grade III or IV splenic injury with angiographic embolization as part of their nonoperative management, provided that they do not have large volume hemoperitoneum or other injuries that require abdominal exploration or medical comorbidities providing a contraindication.",
"   </p>",
"   <p>",
"    Embolization is also relatively contraindicated in patients older than 55 due to higher failure rates in these patients. The splenic capsule thins with age (age &gt;55 years) and may render nonoperative management of higher-grade injuries (&gt;Grade III) in these patients less successful. However, injury severity-adjusted mortality rates do not appear significantly higher in this population compared with younger patients. Retrospective reviews suggest, however, that carefully selected individuals over 55 who are hemodynamically stable, and have no significant medical comorbidities, can also be safely managed with observation, with or without embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/24,30,31\">",
"     24,30,31",
"    </a>",
"    ]. The largest of these studies examined 1008 patients &ge;55 years of age who sustained blunt splenic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/24\">",
"     24",
"    </a>",
"    ]. Of the patients who did not require immediate surgical intervention, 75 percent were successfully managed nonoperatively. Among three age groups, 55 to 64, 65 to 74, and &gt;75 years of age, failure rates for nonoperative management increased and were 19, 27, and 28 percent, respectively, but these differences were not significant, possibly due to the small number of patients in each group. Overall, the experience with nonoperative management of higher grade splenic injury in older patients is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful observation during non-operative management for splenic trauma depends upon proper patient selection, and the availability of adequate resources within the institution [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Patients must be closely monitored by nursing and medical staff, and sufficient flexibility should be available to allow",
"    <span class=\"nowrap\">",
"     urgent/emergent",
"    </span>",
"    intervention should arteriography or surgery be required. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Failure of nonoperative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Wide variation exists in the clinical application of nonoperative strategies but, in general, patients are admitted to a monitored care setting, either an intensive care or step-down unit, depending upon the capabilities of the unit, grade of splenic injury, nature and severity of other injuries, and clinical status [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. We initially place the patient on bed rest, though no clear benefit exists for this practice. We obtain serial hemoglobin levels every six hours in the first 24 hours. Patients are not given a diet (ie, nil per os [NPO]) for at least the first 24 hours. When the hemoglobin level is stable and operative intervention unlikely, the patient may eat.",
"   </p>",
"   <p>",
"    For patients being observed, we do not routinely perform repeat CT imaging during the course of hospitalization. Follow-up study is performed for patients whose clinical situation (ie, falling hemoglobin, increasing abdominal pain, left shoulder pain, fever) indicates a need. In some patients with higher grade injuries (III to V), a repeat scan within 24 to 48 hours may be needed if the clinical situation is unclear, such as in the setting of evolving neurologic injury when the physical examination may be sequentially less reliable than upon admission.",
"   </p>",
"   <p>",
"    The duration of observation should be individualized based upon the grade of splenic injury, nature and severity of other injuries, and the patient's clinical status. In a survey of actively practicing trauma surgeons, there was agreement that higher-grade injury generally required longer observation periods [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/34\">",
"     34",
"    </a>",
"    ]. A common, but not evidence-based practice regarding the duration of observation following splenic injury is that the number of days of observation is equal to the injury grade plus one [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observation period of five days identifies at least 95 percent of patients who would require some form of intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. One multicenter trial found that 86 percent of patients who failed nonoperative management did so within 96 hours of hospital admission, with 61 percent of failures occurring during the first 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/27\">",
"     27",
"    </a>",
"    ]. Patients with higher-grade injuries may require more prolonged periods of observation. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Failure of observation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Failure of observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who fail observation require either splenic embolization, or more commonly, operative management. Patients may fail observational management either as an inpatient or, more rarely, as an outpatient presenting with \"delayed splenic rupture\". It is likely that \"delayed rupture\" more accurately describes those patients with splenic parenchymal pseudoaneurysms, the walls of which degrade during the normal process of clot dissolution with bleeding in a delayed fashion.",
"   </p>",
"   <p>",
"    Indications to pursue intervention include hemodynamic instability, the development of diffuse peritoneal signs, or decreasing hemoglobin attributed to splenic hemorrhage. Hypotension may be absolute or relative, or evidenced as persistent tachycardia in spite of adequate fluid resuscitation. The clinical manifestations of hypovolemia due to blood loss are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H12#H12\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When observing the patient with splenic injury, there is no consensus with respect to level of hemoglobin, change in hemoglobin, or transfusion volume that prompts a need for intervention. Some surgeons intervene prior to the need for any transfusion as a means of avoiding allogeneic exposure, while others make provisions for one to two units of PRBC prior to further intervention.",
"   </p>",
"   <p>",
"    The choice to pursue embolization or surgery in many institutions is governed by the availability of the appropriate resources and the patient's ability to tolerate the time needed to set up the interventional radiology suite (or operating room with dedicated arteriography), get personnel in place, and perform the embolization procedure which, depending upon the patient's anatomy, can be lengthy. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Splenic embolization'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Operative management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Splenic embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiographic embolization was first applied to the management of splenic injury in 1981. Splenic embolization requires specialized imaging facilities and a vascular interventionalist (ie, interventional radiology, vascular surgeon) experienced with celiac artery catheterization and embolization techniques. Success rates for embolization vary depending upon institution, embolization technique, arterial accessibility, operator skill, and the type of embolization material. Where available, embolization is potentially most useful when employed selectively in hemodynamically stable patients who have CT findings that include active contrast extravasation, splenic pseudoaneurysm, or large volume hemoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/11,16,17,39-41\">",
"     11,16,17,39-41",
"    </a>",
"    ]. Retrospective reviews have found variable success rates (57 to 93 percent) for splenic salvage that includes embolization in patients with higher-grade (III, IV, V) splenic injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/10,26,39,41-44\">",
"     10,26,39,41-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of small, retrospective studies have demonstrated that nonoperative management is more successful with the adjunctive use of angio-embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/10,45-48\">",
"     10,45-48",
"    </a>",
"    ]. In one study of 39 patients, splenic artery embolization increased the success rate for nonsurgical management from 74 to 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a cohort analysis, 222 patients with blunt splenic injury treated between 1991 and 1998 were compared with 408 patients treated between 1998 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/47\">",
"     47",
"    </a>",
"    ]. The frequency of nonoperative management (61 versus 85 percent, respectively), injury severity scale (21 versus 27, respectively), frequency of splenic artery embolization (3 versus 23 percent, respectively) and success of nonoperative management (77 versus 96 percent, respectively) all increased significantly between the earlier and later cohort. Hospital mortality rates (12 versus 6 percent) and mean hospital length (15 versus 9 days) decreased significantly.",
"   </p>",
"   <p>",
"    The technique of splenic embolization involves first gaining percutaneous access to the abdominal aorta via the brachial or femoral artery. The celiac axis is cannulated and a celiac arteriogram is performed to confirm the CT findings and evaluate the splenic vasculature. The presence of contrast extravasation from the splenic parenchyma supplied by the short gastric vessels on celiac arteriogram should prompt operative intervention, as these injuries are less amenable to embolization due to the technical difficulties in accessing the short gastric vessels.",
"   </p>",
"   <p>",
"    Embolization of the splenic artery proximally or distally can be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/26\">",
"     26",
"    </a>",
"    ]. Nonrandomized studies have not demonstrated the superiority of one technique over the other, though failure rates for nonoperative management may be greater when proximal embolization is applied to patients with higher-grade injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/49\">",
"     49",
"    </a>",
"    ]. Depending upon the nature of the injury and technical factors, embolization coils, microspheres,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/4/18499?source=see_link\">",
"     absorbable gelatin sponge",
"    </a>",
"    , endogenous clot, or a vascular plug device can be used to interrupt blood flow in major or branch vessels of the spleen effecting total or partial splenic embolization [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/26,50\">",
"     26,50",
"    </a>",
"    ]. Splenic artery embolization may not completely interrupt blood flow from short gastric vessels due to their collateral flow from the left gastric and gastroepiploic arteries. Ongoing bleeding from these vessels may not be obvious with selective splenic artery angiogram, and thus, selective celiac arteriography should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Benefits and risks of nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because there is no operation, surgical risks and potential complications are eliminated with successful nonoperative management. An additional benefit of successful nonoperative management is the preservation of functional splenic tissue. Disadvantages of nonoperative management include an increased risk of missed injury, particularly hollow viscus injury, a risk of delayed bleeding, transfusion-related illness, and, when used, the additional risks associated with embolization techniques.",
"   </p>",
"   <p>",
"    Patients with missed hollow viscus injury present with worsened abdominal pain and the development of peritoneal signs, generally by postinjury day four. These patients require operative intervention and should undergo concomitant definitive management of their splenic injury, if indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26522?source=see_link\">",
"     \"Traumatic gastrointestinal injury in the adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Blood transfusion is associated with complications that can include intravascular volume overload (Transfusion Associated Circulatory Overload [TACO]), transfusion-related acute lung injury (TRALI), hypothermia, coagulopathy, immunologic and allergic reactions as well as immunomodulation (Transfusion Related Immune Modulation, TRIM). Some clinicians feel these risks do not justify nonoperative management strategies, given an uncertain benefit. The risks associated with blood transfusion are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=see_link&amp;anchor=H11#H11\">",
"     \"Use of blood products in the critically ill\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"     \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H6#H6\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Immunosuppression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Splenic embolization is associated with additional risks that include bleeding, pseudoaneurysm formation at the arterial puncture site, splenic infarction,",
"    <span class=\"nowrap\">",
"     splenic/subdiaphragmatic",
"    </span>",
"    abscess, inadvertent embolization of other organs (eg, kidneys) or lower extremities, allergic reaction to contrast and contrast-induced nephropathy. The risk of contrast-induced nephropathy may be greater when embolization is performed following contrast CT scan, especially in patients who may already be volume depleted. Contrast-induced nephropathy and its prevention are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=see_link\">",
"     \"Prevention of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Failure of nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure of nonoperative management (observation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    embolization) is defined as the need for operative intervention, and is generally associated with ongoing bleeding as indicated by the need for ongoing volume expansion or transfusion, or hemodynamic instability. Hypotension may be absolute or relative, or evidenced as persistent tachycardia despite adequate fluid resuscitation. The clinical manifestations of hypovolemia due to blood loss are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link&amp;anchor=H12#H12\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Failure rates for observational management range from 6 to 20 percent and depend upon age, injury severity score, grade of splenic injury, frequency with which embolization techniques are employed, and, most importantly, the appropriateness of patient selection for nonoperative management [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/25,27,28,51\">",
"     25,27,28,51",
"    </a>",
"    ]. In retrospective studies, up to 40 percent of patients failing nonoperative management were found to have inappropriate indications for a nonoperative approach [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/25,52,53\">",
"     25,52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rebleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    secondary splenic \"rupture\" following \"successful\" nonoperative management is a rare but potentially disastrous complication that cannot be reliably predicted. More than 90 percent of secondary splenic \"ruptures\" occur within 10 days following the initial trauma; most of the remainder occur within two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/27,54\">",
"     27,54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Follow-up care",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Resumption of normal activities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon discharge, patients are typically restricted from participation in high-risk activities such as skiing, mountain biking, skydiving, wrestling, contact sports, military combat, and vigorous sexual intercourse for a period of up to three months. While there are no clinical studies to support this duration, one assumes that repeat trauma to the fragile, healing spleen could lead to re-injury [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/34\">",
"     34",
"    </a>",
"    ]. In one retrospective review, healing was demonstrated radiographically within two months of injury in 80 percent of patients; however, grade V injuries were excluded in this study [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;With successful nonoperative management of splenic injury, we do not routinely perform repeat CT imaging. The Eastern Association for the Surgery of Trauma (EAST) guidelines do not support routine follow-up imaging. In one survey of EAST members, 85 percent of respondents did not routinely re-image [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/34\">",
"     34",
"    </a>",
"    ]. The delayed presentation of splenic pseudoaneurysms have been reported and may support a decision to re-image [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/39,56\">",
"     39,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Repeat CT scan or ultrasound (provided that the injury can be adequately visualized) can be considered in select patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/57\">",
"     57",
"    </a>",
"    ]. Re-imaging may be indicated to lift an activity restriction, or for patients whose work requirements or lifestyles place them at higher risk for re-injury if healing is not complete. Examples include professional athletes, military service personnel, and extreme sports enthusiasts. Re-imaging may also be appropriate for those who are planning to travel to regions of the world with limited healthcare access to document complete healing prior to travel. For these patients, re-imaging is typically performed at three months following the injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients sustaining abdominal trauma who are hemodynamically unstable, those who are not candidates for nonoperative management, and those who fail nonoperative management strategies require surgical exploration and either splenic salvage or splenectomy. The choice of procedure depends upon the nature and severity of splenic injury, clinical status of the patient, and associated injuries. Surgical management of traumatic splenic injury is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7049?source=see_link\">",
"     \"Surgical management of splenic injury in the adult trauma patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     IMMUNOCOMPETENCE AFTER SPLENIC INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization is recommended for asplenic patients, since splenectomy impairs opsonization of encapsulated organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Information on specific vaccines and vaccine schedules are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Immunizations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, vaccines are administered either 14 days prior to or 14 days following splenectomy for maximal immunologic benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Delaying vaccinations for 14 days postoperatively increases the antibody response, but may not be feasible in all trauma patients given the historically sporadic follow-up in this patient population. Many centers will therefore vaccinate the patient at the time of discharge, regardless of the postoperative day. Asplenic patients should also receive yearly influenza vaccinations.",
"   </p>",
"   <p>",
"    We recommend that asplenic patients wear medical jewelry and carry medical information cards identifying them as asplenic to alert future healthcare providers under the circumstance that the patient is unable to do so.",
"   </p>",
"   <p>",
"    The need for immunization of patients following treatment for splenic injury compared with those undergoing elective splenectomy is still being defined. We vaccinate all patients who have undergone splenectomy because the extent to which a patient may (or may not) have functional residual splenic tissue (ie, splenosis) is uncertain. Patients with deliberate replantation or spontaneous splenosis have pitted red cell counts (counts less than 15 percent are consistent with immunocompetence) that are lower than those seen in splenectomized patients who do not have splenosis, but the count is not necessarily normal [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following splenic salvage surgery, splenic embolization, or nonoperative management, we feel that immunization is",
"    <strong>",
"     not",
"    </strong>",
"    necessary, though some clinicians may disagree [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. Available in vitro studies indicate immunocompetence in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/65,67-70\">",
"     65,67-70",
"    </a>",
"    ]. As an example, one controlled trial evaluating red blood cell pit counts found no differences for patients following successful nonoperatively managed high-grade injury (0.6 percent), and controls (0.7 percent); counts following splenectomy were 20.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/71\">",
"     71",
"    </a>",
"    ]. Furthermore, in clinical studies of patients undergoing partial splenectomy for reasons other than trauma, humoral immunity was depressed only transiently following partial splenectomy and compared with total splenectomy, partial splenectomy was associated with less risk for postsplenectomy infection [",
"    <a class=\"abstract\" href=\"UTD.htm?1/54/1898/abstract/72,73\">",
"     72,73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Splenic injury can result from either blunt or penetrating chest or abdominal trauma; blunt mechanisms are more common. Splenic injury can also be due to iatrogenic injury during the course of another procedure involving the colon, stomach, pancreas, kidney, or with exposure and reconstruction of the proximal abdominal aorta; the risk is greatest for patients undergoing colon resection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We perform initial resuscitation, diagnostic evaluation, and management of the trauma patient based upon protocols from the Advanced Trauma Life Support (ATLS&reg;) program developed by the American College of Surgeons Committee on Trauma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"       \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"       \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=see_link\">",
"       \"Initial evaluation and management of abdominal stab wounds in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=see_link\">",
"       \"Initial evaluation and management of blunt thoracic trauma in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A suspicion for splenic injury is increased with left upper quadrant",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      left chest trauma; however, clinical history and physical examination are not sufficiently sensitive or specific for the presence of splenic injury. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Trauma evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Findings indicative of splenic injury on focused assessment with sonography for trauma (FAST) examination include findings of perisplenic or free intraperitoneal fluid. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography (CT scan) findings consistent with splenic injury include splenic hypodensity, intraparenchymal or subcapsular hematoma, intravenous contrast blush, active intravenous contrast extravasation or hemoperitoneum. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Splenic injury is graded (I through V) depending upon the extent and depth of splenic hematoma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      laceration identified on CT scan or intraoperatively. Splenic injury grading is one factor used to stratify patient management. Other factors include associated injuries and medical comorbidities. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Splenic injury grading'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Per ATLS protocol, hemodynamically unstable patients with a positive FAST exam or diagnostic peritoneal lavage or aspirate",
"      <span class=\"nowrap\">",
"       (DPL/DPA)",
"      </span>",
"      require operative surgical exploration to determine the source of life-threatening hemorrhage that may be due to splenic injury. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Management approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hemodynamically stable patients with low grade (I to III) injuries, we suggest nonoperative management over definitive surgical intervention (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Observation involves monitored care, serial abdominal examination, and serial hemoglobin assessment, and may involve splenic embolization depending upon resources. Failure of nonoperative management indicates a need for angiographic embolization, if not initially used, or surgical exploration. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Observation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For hemodynamically stable patients with active contrast extravasation or contrast blush on CT scan, we suggest initial splenic embolization over observation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Splenic embolization requires specialized imaging facilities and a suitably experienced interventionalist. Failure of embolization indicates the need for surgery. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Splenic embolization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who develop hemodynamic instability during the course of nonoperative management, we suggest surgical exploration over splenic embolization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Failure of nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asplenic patients are regarded as having impaired immunity to encapsulated organisms and should be immunized against encapsulated organisms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"       \"Prevention of sepsis in the asplenic patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have not undergone splenectomy, either because of successful nonoperative management (ie, observation with or without embolization) or operative splenic salvage, we suggest no immunization (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Immunocompetence after splenic injury'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/1\">",
"      Brady RR, Bandari M, Kerssens JJ, et al. Splenic trauma in Scotland: demographics and outcomes. World J Surg 2007; 31:2111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/2\">",
"      Tan K, Lewis GR, Chahal R, et al. Iatrogenic splenectomy during left nephrectomy: a single-institution experience of eight years. Urol Int 2011; 87:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/3\">",
"      Kamath AS, Iqbal CW, Sarr MG, et al. Colonoscopic splenic injuries: incidence and management. J Gastrointest Surg 2009; 13:2136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/4\">",
"      Cassar K, Munro A. Iatrogenic splenic injury. J R Coll Surg Edinb 2002; 47:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/5\">",
"      Merchea A, Dozois EJ, Wang JK, Larson DW. Anatomic mechanisms for splenic injury during colorectal surgery. Clin Anat 2012; 25:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/6\">",
"      Masoomi H, Carmichael JC, Mills S, et al. Predictive factors of splenic injury in colorectal surgery: data from the Nationwide Inpatient Sample, 2006-2008. Arch Surg 2012; 147:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/7\">",
"      Davis JJ, Cohn I Jr, Nance FC. Diagnosis and management of blunt abdominal trauma. Ann Surg 1976; 183:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/8\">",
"      Salim A, Sangthong B, Martin M, et al. Whole body imaging in blunt multisystem trauma patients without obvious signs of injury: results of a prospective study. Arch Surg 2006; 141:468.",
"     </a>",
"    </li>",
"    <li>",
"     Jacoby, R, Wisner, D. Injury to the Spleen. In: Trauma, 6th ed, Feliciano, D, Mattox, K, Moore, E (Eds), McGraw-Hill Professional, New York, 2008. p.661.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/10\">",
"      Haan JM, Biffl W, Knudson MM, et al. Splenic embolization revisited: a multicenter review. J Trauma 2004; 56:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/11\">",
"      Schurr MJ, Fabian TC, Gavant M, et al. Management of blunt splenic trauma: computed tomographic contrast blush predicts failure of nonoperative management. J Trauma 1995; 39:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/12\">",
"      Hedrick TL, Sawyer RG, Young JS. MRI for the diagnosis of blunt abdominal trauma: a case report. Emerg Radiol 2005; 11:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/13\">",
"      Tinkoff G, Esposito TJ, Reed J, et al. American Association for the Surgery of Trauma Organ Injury Scale I: spleen, liver, and kidney, validation based on the National Trauma Data Bank. J Am Coll Surg 2008; 207:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/14\">",
"      Cohn SM, Arango JI, Myers JG, et al. Computed tomography grading systems poorly predict the need for intervention after spleen and liver injuries. Am Surg 2009; 75:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/15\">",
"      Sutyak JP, Chiu WC, D'Amelio LF, et al. Computed tomography is inaccurate in estimating the severity of adult splenic injury. J Trauma 1995; 39:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/16\">",
"      Becker CD, Spring P, Gl&auml;ttli A, Schweizer W. Blunt splenic trauma in adults: can CT findings be used to determine the need for surgery? AJR Am J Roentgenol 1994; 162:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/17\">",
"      Kohn JS, Clark DE, Isler RJ, Pope CF. Is computed tomographic grading of splenic injury useful in the nonsurgical management of blunt trauma? J Trauma 1994; 36:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/18\">",
"      Harbrecht BG. Is anything new in adult blunt splenic trauma? Am J Surg 2005; 190:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/19\">",
"      Marmery H, Shanmuganathan K, Alexander MT, Mirvis SE. Optimization of selection for nonoperative management of blunt splenic injury: comparison of MDCT grading systems. AJR Am J Roentgenol 2007; 189:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/20\">",
"      Lo A, Matheson AM, Adams D. Impact of concomitant trauma in the management of blunt splenic injuries. N Z Med J 2004; 117:U1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/21\">",
"      Wahl WL, Ahrns KS, Chen S, et al. Blunt splenic injury: operation versus angiographic embolization. Surgery 2004; 136:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/22\">",
"      Holubar SD, Wang JK, Wolff BG, et al. Splenic salvage after intraoperative splenic injury during colectomy. Arch Surg 2009; 144:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/23\">",
"      Stein DM, Scalea TM. Nonoperative management of spleen and liver injuries. J Intensive Care Med 2006; 21:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/24\">",
"      Siriratsivawong K, Zenati M, Watson GA, Harbrecht BG. Nonoperative management of blunt splenic trauma in the elderly: does age play a role? Am Surg 2007; 73:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/25\">",
"      McIntyre LK, Schiff M, Jurkovich GJ. Failure of nonoperative management of splenic injuries: causes and consequences. Arch Surg 2005; 140:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/26\">",
"      Bhullar IS, Frykberg ER, Siragusa D, et al. Selective angiographic embolization of blunt splenic traumatic injuries in adults decreases failure rate of nonoperative management. J Trauma Acute Care Surg 2012; 72:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/27\">",
"      Peitzman AB, Heil B, Rivera L, et al. Blunt splenic injury in adults: Multi-institutional Study of the Eastern Association for the Surgery of Trauma. J Trauma 2000; 49:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/28\">",
"      Bhangu A, Nepogodiev D, Lal N, Bowley DM. Meta-analysis of predictive factors and outcomes for failure of non-operative management of blunt splenic trauma. Injury 2012; 43:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/29\">",
"      Watson GA, Rosengart MR, Zenati MS, et al. Nonoperative management of severe blunt splenic injury: are we getting better? J Trauma 2006; 61:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/30\">",
"      Godley CD, Warren RL, Sheridan RL, McCabe CJ. Nonoperative management of blunt splenic injury in adults: age over 55 years as a powerful indicator for failure. J Am Coll Surg 1996; 183:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/31\">",
"      Krause KR, Howells GA, Bair HA, et al. Nonoperative management of blunt splenic injury in adults 55 years and older: a twenty-year experience. Am Surg 2000; 66:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/32\">",
"      Demetriades D, Hadjizacharia P, Constantinou C, et al. Selective nonoperative management of penetrating abdominal solid organ injuries. Ann Surg 2006; 244:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/33\">",
"      Harbrecht BG, Zenati MS, Ochoa JB, et al. Management of adult blunt splenic injuries: comparison between level I and level II trauma centers. J Am Coll Surg 2004; 198:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/34\">",
"      Fata P, Robinson L, Fakhry SM. A survey of EAST member practices in blunt splenic injury: a description of current trends and opportunities for improvement. J Trauma 2005; 59:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/35\">",
"      Gomez D, Haas B, Al-Ali K, et al. Controversies in the management of splenic trauma. Injury 2012; 43:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/36\">",
"      St Peter SD, Keckler SJ, Spilde TL, et al. Justification for an abbreviated protocol in the management of blunt spleen and liver injury in children. J Pediatr Surg 2008; 43:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/37\">",
"      McCray VW, Davis JW, Lemaster D, Parks SN. Observation for nonoperative management of the spleen: how long is long enough? J Trauma 2008; 65:1354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/38\">",
"      Smith J, Armen S, Cook CH, Martin LC. Blunt splenic injuries: have we watched long enough? J Trauma 2008; 64:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/39\">",
"      Davis KA, Fabian TC, Croce MA, et al. Improved success in nonoperative management of blunt splenic injuries: embolization of splenic artery pseudoaneurysms. J Trauma 1998; 44:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/40\">",
"      Sclafani SJ. The role of angiographic hemostasis in salvage of the injured spleen. Radiology 1981; 141:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/41\">",
"      Raikhlin A, Baerlocher MO, Asch MR, Myers A. Imaging and transcatheter arterial embolization for traumatic splenic injuries: review of the literature. Can J Surg 2008; 51:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/42\">",
"      Gaarder C, Dormagen JB, Eken T, et al. Nonoperative management of splenic injuries: improved results with angioembolization. J Trauma 2006; 61:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/43\">",
"      Harbrecht BG, Ko SH, Watson GA, et al. Angiography for blunt splenic trauma does not improve the success rate of nonoperative management. J Trauma 2007; 63:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/44\">",
"      Smith HE, Biffl WL, Majercik SD, et al. Splenic artery embolization: Have we gone too far? J Trauma 2006; 61:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/45\">",
"      Haan J, Ilahi ON, Kramer M, et al. Protocol-driven nonoperative management in patients with blunt splenic trauma and minimal associated injury decreases length of stay. J Trauma 2003; 55:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/46\">",
"      Liu PP, Lee WC, Cheng YF, et al. Use of splenic artery embolization as an adjunct to nonsurgical management of blunt splenic injury. J Trauma 2004; 56:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/47\">",
"      Rajani RR, Claridge JA, Yowler CJ, et al. Improved outcome of adult blunt splenic injury: a cohort analysis. Surgery 2006; 140:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/48\">",
"      Sabe AA, Claridge JA, Rosenblum DI, et al. The effects of splenic artery embolization on nonoperative management of blunt splenic injury: a 16-year experience. J Trauma 2009; 67:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/49\">",
"      Duchesne JC, Simmons JD, Schmieg RE Jr, et al. Proximal splenic angioembolization does not improve outcomes in treating blunt splenic injuries compared with splenectomy: a cohort analysis. J Trauma 2008; 65:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/50\">",
"      Ng EH, Comin J, David E, et al. AMPLATZER Vascular Plug 4 for proximal splenic artery embolization in blunt trauma. J Vasc Interv Radiol 2012; 23:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/51\">",
"      Bala M, Edden Y, Mintz Y, et al. Blunt splenic trauma: predictors for successful non-operative management. Isr Med Assoc J 2007; 9:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/52\">",
"      Peitzman AB, Harbrecht BG, Rivera L, et al. Failure of observation of blunt splenic injury in adults: variability in practice and adverse consequences. J Am Coll Surg 2005; 201:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/53\">",
"      Liu PP, Liu HT, Hsieh TM, et al. Nonsurgical management of delayed splenic rupture after blunt trauma. J Trauma Acute Care Surg 2012; 72:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/54\">",
"      Gauer JM, Gerber-Paulet S, Seiler C, Schweizer WP. Twenty years of splenic preservation in trauma: lower early infection rate than in splenectomy. World J Surg 2008; 32:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/55\">",
"      Savage SA, Zarzaur BL, Magnotti LJ, et al. The evolution of blunt splenic injury: resolution and progression. J Trauma 2008; 64:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/56\">",
"      Norotsky MC, Rogers FB, Shackford SR. Delayed presentation of splenic artery pseudoaneurysms following blunt abdominal trauma: case reports. J Trauma 1995; 38:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/57\">",
"      Terrell TR, Lundquist B. Management of splenic rupture and return-to-play decisions in a college football player. Clin J Sport Med 2002; 12:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/58\">",
"      Schwartz PE, Sterioff S, Mucha P, et al. Postsplenectomy sepsis and mortality in adults. JAMA 1982; 248:2279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/59\">",
"      Styrt B. Infection associated with asplenia: risks, mechanisms, and prevention. Am J Med 1990; 88:33N.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/60\">",
"      Howdieshell TR, Heffernan D, Dipiro JT, Therapeutic Agents Committee of the Surgical Infection Society. Surgical infection society guidelines for vaccination after traumatic injury. Surg Infect (Larchmt) 2006; 7:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/61\">",
"      Centers for Disease Control and Prevention (CDC). Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep 2009; 58:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/62\">",
"      Traub A, Giebink GS, Smith C, et al. Splenic reticuloendothelial function after splenectomy, spleen repair, and spleen autotransplantation. N Engl J Med 1987; 317:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/63\">",
"      Shatz DV. Vaccination practices among North American trauma surgeons in splenectomy for trauma. J Trauma 2002; 53:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/64\">",
"      Di Sabatino A, Carsetti R, Corazza GR. Post-splenectomy and hyposplenic states. Lancet 2011; 378:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/65\">",
"      Pirasteh A, Snyder LL, Lin R, et al. Temporal assessment of splenic function in patients who have undergone percutaneous image-guided splenic artery embolization in the setting of trauma. J Vasc Interv Radiol 2012; 23:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/66\">",
"      Skattum J, Naess PA, Gaarder C. Non-operative management and immune function after splenic injury. Br J Surg 2012; 99 Suppl 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/67\">",
"      Resende V, Petroianu A. Functions of the splenic remnant after subtotal splenectomy for treatment of severe splenic injuries. Am J Surg 2003; 185:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/68\">",
"      Nakae H, Shimazu T, Miyauchi H, et al. Does splenic preservation treatment (embolization, splenorrhaphy, and partial splenectomy) improve immunologic function and long-term prognosis after splenic injury? J Trauma 2009; 67:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/69\">",
"      Tominaga GT, Simon FJ Jr, Dandan IS, et al. Immunologic function after splenic embolization, is there a difference? J Trauma 2009; 67:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/70\">",
"      Skattum J, Titze TL, Dormagen JB, et al. Preserved splenic function after angioembolisation of high grade injury. Injury 2012; 43:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/71\">",
"      Falimirski M, Syed A, Prybilla D. Immunocompetence of the severely injured spleen verified by differential interference contrast microscopy: the red blood cell pit test. J Trauma 2007; 63:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/72\">",
"      Bader-Meunier B, Gauthier F, Archambaud F, et al. Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. Blood 2001; 97:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?1/54/1898/abstract/73\">",
"      Sheikha AK, Salih ZT, Kasnazan KH, et al. Prevention of overwhelming postsplenectomy infection in thalassemia patients by partial rather than total splenectomy. Can J Surg 2007; 50:382.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7957 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1898=[""].join("\n");
var outline_f1_54_1898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SPLENIC ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRAUMA EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Associated injuries",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2380934350\">",
"      - FAST findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2380934357\">",
"      - CT findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2380934399\">",
"      - Other imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SPLENIC INJURY GRADING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NONOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Contraindications to nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Failure of observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Splenic embolization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Benefits and risks of nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Failure of nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Follow-up care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Resumption of normal activities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      IMMUNOCOMPETENCE AFTER SPLENIC INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/7957\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/7957|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/12/30919\" title=\"picture 1\">",
"      Low grade spleen laceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/34/26151\" title=\"picture 2\">",
"      High grade spleen laceration",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/30/36330?source=related_link\">",
"      Fish oil and marine omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=related_link\">",
"      Initial evaluation and management of abdominal gunshot wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12776?source=related_link\">",
"      Initial evaluation and management of abdominal stab wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34426?source=related_link\">",
"      Initial evaluation and management of blunt thoracic trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/42/35498?source=related_link\">",
"      Prevention of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17032?source=related_link\">",
"      Principles of computed tomography of the chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7049?source=related_link\">",
"      Surgical management of splenic injury in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26522?source=related_link\">",
"      Traumatic gastrointestinal injury in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f1_54_1899="Common AIDS-defining conditions US children";
var content_f1_54_1899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common AIDS-defining conditions in United States children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Pneumocystis carinii pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoid interstitial pneumonia/pulmonary lymphoid hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent bacterial infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wasting syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Candida esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HIV encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cytomegalovirus disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1899=[""].join("\n");
var outline_f1_54_1899=null;
var title_f1_54_1900="Staging classification AIDS KS";
var content_f1_54_1900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F54626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F54626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Staging classification for AIDS-related KS",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Good risk (all of the",
"following)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Poor risk (any of the",
"following)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumor, T",
"       </td>",
"       <td>",
"        T0: Confined to skin and/or lymph nodes and/or minimal",
"oral disease (non-nodular KS confined to palate)",
"       </td>",
"       <td>",
"        <p>",
"         T1:Tumor-associated edema or ulceration",
"        </p>",
"        <p>",
"         Extensive oral KS",
"        </p>",
"        <p>",
"         Gastrointestinal KS",
"        </p>",
"        <p>",
"         KS in other non-nodal viscera",
"        </p>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune",
"system, I",
"       </td>",
"       <td>",
"        I0: CD4 cell count &gt;200/&micro;L*",
"       </td>",
"       <td>",
"        I1: CD4 cell count &lt;200/&micro;L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic illness, S",
"       </td>",
"       <td>",
"        <p>",
"         S0: No history of OI or thrush&bull;",
"        </p>",
"        <p>",
"         No \"B\" symptoms&Delta;",
"        </p>",
"        <p>",
"         Karnofsky performance status &gt;70&nbsp;",
"        </p>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         S1: History of OI and/or thrush",
"        </p>",
"        <p>",
"         \"B\" symptoms present",
"        </p>",
"        <p>",
"         Karnofsky performance status &lt;70",
"        </p>",
"        <p>",
"         Other HIV-related illness (eg, neurologic disease,",
"lymphoma)",
"        </p>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A CD4 lymphocyte cut-off of 150 &micro;L may be more discriminatory. (Krown, SE, Testa, MA, Huang, J. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15:3085.)",
"     <br>",
"      &bull; OI is opportunistic infection.",
"      <br>",
"       &Delta; \"B\" symptoms are unexplained fever, night sweats, &lt;10 percent involuntary weight loss, or diarrhea persisting more than two weeks.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Krown, SE, Metroka, C, Wernz, JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1989; 7:1201.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1900=[""].join("\n");
var outline_f1_54_1900=null;
var title_f1_54_1901="Poisoning home survey";
var content_f1_54_1901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F66415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F66415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Poisoning prevention home survey",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Area",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preventive approaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Kitchen",
"       </td>",
"       <td>",
"        Store detergents, oven cleaners, and drain cleaners on higher shelves.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store safe items in cabinets and drawers that are within the child's reach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Install child-guard latches on cabinet doors and drawers that contain dangerous items.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid storage of chemicals in the refrigerator.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not use insecticides, traps, or baits in locations to which children have access.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Bathroom",
"       </td>",
"       <td>",
"        Store medications out of sight and out of reach, preferably in a locked cabinet, box, or closet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store perfumes, colognes, cosmetics, and hair care products out of sight and out of reach (eg, on upper shelves, or in locked containers).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not use insecticides, traps, or baits in locations to which children have access.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Bedrooms",
"       </td>",
"       <td>",
"        Store medications and contraceptives out of sight and out of reach, preferably in a locked cabinet, box, or closet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store perfumes, colognes, cosmetics and hair care products out of sight and out of reach (eg, on upper shelves, or in locked containers).",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Living and dining rooms",
"       </td>",
"       <td>",
"        Remove toxic plants or keep them out of reach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep tobacco products, lighters, and matches out of sight and out of reach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Keep alcohol in a locked cabinet; dispose of partially consumed drinks.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Laundry",
"       </td>",
"       <td>",
"        Keep cleaning supplies out of reach.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Garage/basement",
"       </td>",
"       <td>",
"        Store paints, solvents, insecticides, herbicides, and chemicals for use in hobbies in locked cabinets; always store these materials in the original containers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not use insecticides, traps, or baits in locations to which children have access.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Install a carbon monoxide detector.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Outdoor areas",
"       </td>",
"       <td>",
"        Identify toxic plants, berries, and bulbs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not leave unplanted bulbs in areas to which children have access.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Miscellaneous",
"       </td>",
"       <td>",
"        Check and secure (with tape) battery compartments on household products.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Store batteries out of the reach and sight of children.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not allow children to play with batteries.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      <ol>",
"       <li>",
"        Committee on Injury and Poison Prevention, American Academy of Pediatrics. Injury prevention in and around the home. In: Injury Prevention and Control for Children and Youth. American Academy of Pediatrics, Elk Grove Village, IL 1997. p.47.",
"       </li>",
"       <li>",
"        Litovitz T, Whitaker N, Clark L. Preventing battery ingestions: an analysis of 8648 cases. Pediatrics 2010; 125:1178.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1901=[""].join("\n");
var outline_f1_54_1901=null;
var title_f1_54_1902="Post MI survival in patients with VT or VF";
var content_f1_54_1902=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74805&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Sustained ventricular arrhythmias after myocardial infarction (MI) decrease survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 293px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the GUSTO-1 trial of 40,825 patients, the in-hospital and one year mortality rates were higher in those who had sustained ventricular tachcardia (VT) or ventricular fibrillation (VF) compared to those without either arrhythmia. The group with both VT and VF had highest mortality rates.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Newby, KH, Thompson, T, Stebbins, A, et al, Circulation 1998; 98:2567.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1902=[""].join("\n");
var outline_f1_54_1902=null;
var title_f1_54_1903="Cervical extension teardrop fracture";
var content_f1_54_1903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical extension teardrop fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The extension teardrop fracture occurs when abrupt neck extension causes the anterior longitudinal ligament to pull the anteroinferior corner away from the remainder of the vertebral body, producing a triangular-shaped fragment (red arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f1_54_1903=[""].join("\n");
var outline_f1_54_1903=null;
